Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma

British Journal of Haematology

Volumn 154, Issue 2, 2011, Pages 284-286

  Fanale, Michelle ^a   Fayad, Luis ^a   Pro, Barbara ^b   Samaniego, Felipe ^a   Liboon, Mary Joy ^a   Nunez, Cesar ^a   Horowitz, Sandra ^a   Anderlini, Paolo ^a   Popat, Uday ^a   Ji, Yuan ^a   Kwak, Larry W ^a   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Bortezomib; Hodgkin lymphoma; ICE; Relapsed

Indexed keywords

AMINOTRANSFERASE; ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; BORTEZOMIB; BUSULFAN; CARBOPLATIN; CARMUSTINE; CIPROFLOXACIN; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; GEMCITABINE; IFOSFAMIDE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VALACICLOVIR; VINBLASTINE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; APHERESIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER RELAPSE; CD34 SELECTION; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FOLLOW UP; HODGKIN DISEASE; HUMAN; LETTER; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CARBOPLATIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; HODGKIN DISEASE; HUMANS; IFOSFAMIDE; PYRAZINES; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959848266     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08618.x     Document Type: Letter

References (9)

1. Blum, K.A., Johnson, J.L., Niedzwiecki, D., Cannellos, G.P., Cheson, B.D. & Bartlett, N.L. (2006) A phase II study of bortezomib in relapsed Hodgkin lymphoma: preliminary results of CALGB 50206. Journal of Clinical Oncology Annual Meeting Abstracts, 24, 7576.
2. Filmont, J.E., Gisselbrecht, C., Cuenca, X., Deville, L., Ertault, M., Brice, P., De Kerviler, E., Briere, J., Larghero, J., Moretti, J.L. & Mounier, N. (2007) The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer, 110, 1361-1369.
3. Ji, Y., Li, Y. & Nebiyou Bekele, B. (2007) Dose-finding in phase I clinical trials based on toxicity probability intervals. Clinical Trials, 4, 235-244.
4. Moskowitz, C.H., Nimer, S.D., Zelenetz, A.D., Trippett, T., Hedrick, E.E., Filippa, D.A., Louie, D., Gonzales, M., Walits, J., Coady-Lyons, N., Qin, J., Frank, R., Bertino, J.R., Goy, A., Noy, A., O'Brien, J.P., Straus, D., Portlock, C.S. & Yahalom, J. (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood, 97, 616-623.
5. Schot, B.W., Zijlstra, J.M., Sluiter, W.J., van Imhoff, G.W., Pruim, J., Vaalburg, W. & Vellenga, E. (2007) Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood, 109, 486-491.
6. Strauss, S.J., Maharaj, L., Hoare, S., Johnson, P.W., Radford, J.A., Vinnecombe, S., Millard, L., Rohatiner, A., Boral, A., Trehu, E., Schenkein, D., Balkwill, F., Joel, S.P. & Lister, T.A. (2006) Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. Journal of Clinical Oncology, 24, 2105-2112.
7. Trelle, S., Sezer, O., Naumann, R., Rummel, M., Keller, U., Nickelsen, M., engert, A. & Borchmann, P. (2006) Bortezomib is not active in patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study. Blood (ASH Annual Meeting Abstracts), 108, 2477.
8. Younes, A., Pro, B. & Fayad, L. (2006) Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood, 107, 1731-1732.
9. Zheng, B., Georgakis, G.V., Li, Y., Bharti, A., McConkey, D., Aggarwal, B.B. & Younes, A. (2004) Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clinical Cancer Research, 10, 3207-3215.